Clover Health CEO Jamie Reynoso Sells Nearly 4,900 Shares Under Pre-Established Trading Plan

Executive Share Disposition at Clover Health

Jamie L. Reynoso, identified in the disclosure as CEO of Medicare Advantage operations at Clover Health Investments Corp., completed a stock sale transaction on July 17, 2026. The transaction involved the sale of 4,839 shares of the company's Class A Common Stock. Following this sale, Reynoso maintained beneficial ownership of 2,814,640 shares of Class A Common Stock, demonstrating continued substantial equity stake in the Delaware-incorporated healthcare company.

The Medicare Advantage sector has been a critical focus for Clover Health's business model, representing a key operational segment where the company delivers healthcare services and insurance coverage to eligible beneficiaries. Reynoso's continued significant shareholding following this transaction indicates meaningful personal financial alignment with the company's performance and strategic direction in this market segment. The scale of his remaining ownership position relative to the shares sold suggests confidence in the company's longer-term prospects despite the near-term transaction activity.

Rule 10b5-1 Trading Plan Structure and Execution

The share sale was conducted pursuant to a Rule 10b5-1 trading plan that Reynoso adopted on March 12, 2026. Under Securities and Exchange Commission regulations, Rule 10b5-1 trading plans allow corporate insiders to establish predetermined schedules for buying or selling securities. Once adopted, these plans operate independently of the executive's knowledge of material nonpublic information, providing a structured mechanism for insider stock transactions that complies with insider trading restrictions. The plan structure protects both the executive and the company by demonstrating that trades were not timed based on confidential business developments.

The actual execution of shares under the plan occurred on the transaction date of July 17, 2026. Individual share sales within this transaction were completed at varying prices, demonstrating that the overall weighted average calculation reflects multiple execution points rather than a single trade price. This multi-execution approach is common when large share volumes are transacted over a period, as brokers typically seek to minimize market impact and achieve favorable execution across different price points throughout a trading session or over several trading days.

Pricing Details and Share Sale Parameters

The weighted average sale price reported in the disclosure was $4.53 per share. However, the actual individual transactions within this sale were executed at prices ranging from a low of $4.35 per share to a high of $4.63 per share. This $0.28 price spread across the transaction represents approximately 6.4 percent variation from the lowest to highest execution price. The company disclosed that Reynoso undertakes to provide full information regarding the number of shares sold at each separate price within this range to the issuer, shareholders, or SEC staff upon request, maintaining transparency regarding the specific execution mechanics of the transaction.

The pricing environment at the time of the July 17, 2026 transaction reflects the market valuation of Clover Health's Class A Common Stock during that period. Investors analyzing insider transactions often examine share prices at the time of sale in relation to broader equity market conditions, company-specific performance metrics, and sector-wide trends affecting healthcare insurance and Medicare Advantage operators. The filing does not provide commentary on market conditions or the reasoning behind the specific timing of the sale within the pre-established trading plan.

Beneficial Ownership Position and Insider Status

Following the completion of this transaction, Jamie L. Reynoso's direct beneficial ownership in Clover Health stands at 2,814,640 shares of Class A Common Stock. All shares are held in direct beneficial ownership form, meaning Reynoso has direct legal title and control over these securities rather than owning them indirectly through trusts, partnerships, or other entities. The Form 4 disclosure indicates that Reynoso is subject to Section 16 reporting requirements as an officer of the company, specifically in his capacity as CEO of the Medicare Advantage business segment.

The substantial shareholding maintained by Reynoso following this partial sale demonstrates a meaningful personal financial interest in the company's operational performance and stock price appreciation. Insider ownership levels are frequently monitored by investors as an indicator of management confidence in corporate prospects. The fact that Reynoso retains millions of shares while executing a sale under a pre-established plan suggests a balanced approach to personal wealth management while maintaining significant skin in the game alongside other shareholders.

Medicare Advantage Operations and Business Context

Clover Health Investments Corp. operates as a healthcare company focused on delivering services within the Medicare Advantage insurance market. Medicare Advantage represents a significant and growing segment of the senior healthcare market, where private insurance companies contract with the Centers for Medicare and Medicaid Services to provide benefits to eligible beneficiaries aged 65 and older. This business model generates revenue through capitated payments from CMS and premium revenues from beneficiaries, creating a distinct financial structure compared to traditional fee-for-service healthcare delivery.

The company's emphasis on its Medicare Advantage operations, as reflected in Reynoso's title designation, underscores the strategic importance of this market segment to Clover Health's business model and growth strategy. The Medicare Advantage sector has experienced significant competitive dynamics, regulatory changes, and market consolidation in recent years. Clover Health's positioning within this market segment, combined with Reynoso's executive leadership responsibility for these operations, places the company within a healthcare insurance ecosystem that is subject to CMS payment adjustments, quality metrics requirements, and ongoing regulatory scrutiny at both federal and state levels.

Form 4 Filing Requirements and Regulatory Compliance

The disclosure was filed as a Form 4 report with the Securities and Exchange Commission on July 17, 2026, the same date as the underlying transaction. Form 4 filings are required under Section 16(a) of the Securities Exchange Act of 1934 whenever officers, directors, or principal shareholders of publicly traded companies execute transactions in company securities. The requirement to file within two business days of the transaction completion provides investors and market participants with timely information regarding insider trading activity, supporting market transparency and informed investment decision-making.

The filing was executed by Peter J. Rivas in his capacity as attorney-in-fact for Jamie L. Reynoso, a common practice that allows designated representatives to file required regulatory documents on behalf of executives. The Form 4 document contains representations regarding the accuracy and completeness of the information provided, with specific acknowledgment that intentional misstatements or omissions constitute federal criminal violations under applicable securities law. This legal framework underscores the significance of accurate insider transaction reporting and the regulatory enforcement mechanisms that support market integrity.

Trading Plan Adoption and Pre-Planned Trading Strategy

The Rule 10b5-1 trading plan adopted by Reynoso on March 12, 2026, established the framework within which the July 17, 2026 sale occurred. Adoption of such trading plans by company executives is a common practice, allowing predetermined share transactions to occur without requiring individual judgments about timing relative to company information. The approximately four-month interval between plan adoption on March 12 and the actual sale execution on July 17 reflects the operational structure of such plans, which typically establish selling schedules that unfold over defined periods to achieve diversified execution timing and pricing.

Investors and analysts often view the establishment and execution of Rule 10b5-1 trading plans as part of normal executive compensation management and personal financial planning rather than indicators of company-specific concerns or insider pessimism. These plans allow executives to maintain consistent personal financial strategies regardless of their ongoing awareness of company developments. The disclosure confirms that Reynoso's transaction was specifically executed pursuant to such a plan, providing regulatory assurance that the sale timing was predetermined rather than responsive to market opportunities or information advantages.

Shareholder and Investor Implications

Insider transactions reported on Form 4 filings receive varying levels of attention from market participants, with some investors viewing insider selling as potentially negative and others viewing it as a normal part of executive compensation realization and personal wealth diversification. In this case, the sale represents approximately 0.17 percent of Reynoso's total beneficial ownership position, indicating a relatively modest reduction in his shareholding relative to his total equity stake. The fact that the transaction occurred under a pre-established trading plan, rather than representing a discretionary decision made in response to current circumstances, may influence how investors and analysts interpret the transaction's significance.

The immediate share price impact was not clear from available public information. Market prices for CLOV shares reflect many factors including company operational performance, Medicare Advantage market conditions, CMS payment policies, competitive developments, and broader healthcare sector trends. A single insider transaction of this scale is unlikely to materially influence share price on its own, though patterns of insider buying or selling activity across multiple executives can sometimes be viewed as indicative of management sentiment regarding company prospects. Investors analyzing this transaction may wish to consider it within the context of broader insider trading patterns and company operational updates.

Disclosure Transparency and Regulatory Framework

The detailed disclosure provided in the Form 4 report, including the price range information and commitment to provide specific transaction details upon request, demonstrates the regulatory framework designed to promote transparency in insider transactions. The requirement that Reynoso undertake to provide information regarding the number of shares sold at each separate price within the stated range ensures that market participants can access granular execution details if desired. This transparency framework supports investor confidence in securities markets by providing verifiable information regarding insider trading activity at publicly traded companies.

The SEC's regulation of insider transactions through the Form 4 reporting process, combined with the Rule 10b5-1 trading plan framework, creates multiple layers of compliance oversight. These mechanisms help ensure that insider transactions are not motivated by material nonpublic information and are properly disclosed to the investing public. Clover Health's compliance with these reporting requirements, as evidenced by the timely filing of this Form 4 disclosure, demonstrates adherence to regulatory obligations applicable to public companies and their senior executives within the NASDAQ-listed healthcare sector.